Autres langues TG Therapeutics, Inc.

Actions

TGTX

US88322Q1085

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
13,47 ^USD	-3,16 %		-2,25 %	-21,14 %

18/04	TG Therapeutics remporte le contrat des Anciens Combattants pour le médicament Briumvi contre la sclérose en plaques	MT
18/04	Tg Therapeutics, Inc. obtient un contrat national du ministère des Anciens Combattants pour Briumvi, l'anti-Cd20 préféré pour les formes rémittentes de la sclérose en plaques	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

TG Therapeutics Announces Additional Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	19/04
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	18/04
Sector Update: Health Care	18/04
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	18/04
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	18/04
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis	18/04
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	18/04
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	16/04
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	15/04
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	13/03
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	08/03
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	04/03
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile	01/03
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	01/03
Sector Update: Health Care Stocks Softer Wednesday Afternoon	28/02
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	28/02
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	28/02
TG Therapeutics: Q4 Earnings Snapshot	28/02
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q4 Revenue $44M, vs. Street Est of $40.1M	28/02
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results	28/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues TG Therapeutics, Inc.

Actions

TGTX

US88322Q1085

Autres langues

Filtres